Elsevier

Clinical Immunology

Volume 235, February 2022, 108380
Clinical Immunology

Review Article
Gut dysbiosis and multiple sclerosis

https://doi.org/10.1016/j.clim.2020.108380Get rights and content

Highlights

  • Multiple sclerosis (MS) is an inflammatory disease of the central nervous system.

  • Many studies revealed gut dysbiosis in MS patients.

  • Animal studies revealed the association between gut microbiota and MS pathogenesis.

  • Metabolites of microbiota affect the resident cells in the central nervous system.

  • Further analysis is needed to elucidate the interaction between dysbiosis and MS.

Abstract

Multiple sclerosis (MS) is an inflammatory disease of the central nervous system (CNS) and T cell-mediated autoimmune processes are assumed to be involved in its pathogenesis. Recently, accumulating evidence has indicated that commensal bacteria interact with the host immune system and that the alteration of commensal bacteria composition, termed dysbiosis, is associated with various autoimmune diseases including CNS autoimmune diseases. In this review, we introduce recent findings regarding the association between gut microbiota and MS and related diseases and microbiota function in an animal model of MS.

Introduction

Multiple sclerosis (MS) is a chronic demyelinating inflammatory disease of the central nervous system (CNS). In the CNS of MS patients, multiple demyelinating lesions accompanied by lymphocyte infiltration and antibody and complement deposition develop repeatedly, which induces various neurological symptoms. Most patients with MS have a relapsing-remitting disease course (RRMS) during the early disease stage. However, some patients proceed to a progressive phase characterized by the accumulation of irreversible neurological disabilities in later disease stages [1]. It is assumed that MS pathogenesis is mediated through an autoimmune response where T cells become reactive to myelin autoantigens such as myelin basic protein (MBP) [2]. Although the pathogenesis of autoimmune responses to myelin autoantigens is still poorly understood, epidemiological studies have revealed that genetic and environmental factors are involved in the development of MS [3,4]. Genome-wide association studies of MS revealed that many genes associated with the differentiation, activation, and proliferation of CD4+ helper T cells are linked to MS susceptibility, which suggests that cellular autoimmunity is a major factor in MS pathogenesis [[5], [6], [7], [8]]. Accumulating evidence has indicated that IFN-γ-producing Th1 cells and pathogenic Th17 cells, capable of producing TNF-α and GM-CSF in addition to IL-17, IL-21 and IL-22, play an important role in the development of experimental autoimmune encephalomyelitis (EAE), an animal model of MS [[9], [10], [11]]. The development of CNS autoimmunity is likely to be triggered by a shift in the delicate balance between pathogenic Th17/Th1 cells and immune regulatory cells such as Foxp3+ regulatory T cells (Treg cells). Additionally, most currently available disease-modifying treatments affect the proliferation, activation, or migration of T cells [12], which further indicates the important roles of T cells in the pathogenesis of MS. Recently, emerging evidence based on the efficacy of anti-CD20 therapy has indicated the importance of B cells in CNS inflammation. The presence of oligoclonal bands (OCB) in cerebrospinal fluid, a characteristic finding of MS, suggests the intrathecal production of immunoglobulin. Although the pathogenicity and autoantigen recognized by these intrathecal immunoglobulins are still unknown, many studies have reported that antibody-independent functions of B cells including antigen presentation, modulation of T cell responses, and cytokine production, are involved in MS pathology and can have pathogenic and protective effects [13].

Many environmental factors have been reported to be associated with the onset of MS, including vitamin D, obesity in early life, infection with Epstein–Barr virus, cigarette smoking, and salt intake [3]. Recently, the association of gut microbiota and various CNS diseases including neurodegenerative diseases, psychiatric diseases, and neuroinflammatory diseases such as MS have attracted attention [14,15]. In this review, we summarize recent findings about the interaction between the gut microbiota and MS and related diseases.

Section snippets

Gut microbiota and the immune system

The human body is colonized by many microbial cells. An estimated 3.8 × 1013 bacteria, which consist of hundreds of species, exist in the human intestinal tract and form a huge system termed the gut microbiota [16]. The intestinal tract is the largest immune organ in the body, containing about 100 billion lymphocytes. Because the intestinal mucosa is the entry point for many pathogens, the gut immune system must exclude these pathogens. Additionally, the gut immune system must be regulated

Gut dysbiosis in RRMS

Today, various neurological and psychiatric diseases, including Parkinson's disease, Alzheimer's disease, major depressive disorder, autism and MS, are thought to be associated with alterations in the composition of the gut microbiota, termed dysbiosis (Table 1) [71]. Cantarel et al. analyzed fecal samples from seven MS patients and eight healthy controls in the USA and reported a decrease of Faecalibacterium in MS patients [72]. They also investigated differences in the bacterial composition

Antibiotics and germ-free conditions

To elucidate an association between the gut microbiota and CNS autoimmunity, an experimental approach using an animal model has been studied extensively (Table 2). EAE, the most common animal model of MS, is characterized by T-cell mediated autoimmune inflammation and demyelination. Usually, EAE can be induced by active immunization with a myelin peptide (active EAE) or the adoptive transfer of encephalitogenic T cells (passive EAE). In the early 1990s it was reported that MBP-specific

Conclusion

To date, many studies have reported a relationship between the gut microbiota and MS or its animal models. Studies have reported that in the gut of MS patients, several genera of microbiota including Akkermansia and Streptococcus are increased, and various genera mainly belonging to Firmicutes or Bacteroidetes, are reduced. Of note, studies have reported a decrease in the SCFA-producing microbiome in MS patients, suggesting the importance of microbiota metabolites including SCFAs in MS

Declaration of Competing Interest

The authors declare no competing financial interests.

Acknowledgment

We thank J. Ludovic Croxford, PhD, from Edanz Group (www.edanzediting.com/ac) for editing a draft of this manuscript. This work was supported by JSPS KAKENHI Grant Numbers JP24229006 and JP26293234, and by AMED under Grant Number JP18ek0109189.

References (139)

  • J. von Gerichten et al.

    Diastereomer-specific quantification of bioactive hexosylceramides from bacteria and mammals

    J. Lipid Res.

    (2017)
  • H. Yokote et al.

    NKT cell-dependent amelioration of a mouse model of multiple sclerosis by altering gut flora

    Am. J. Pathol.

    (2008)
  • S.B.G. Eckle et al.

    Recognition of vitamin B precursors and byproducts by mucosal associated invariant T cells

    J. Biol. Chem.

    (2015)
  • M. Colonna

    Innate lymphoid cells: diversity, plasticity, and unique functions in immunity

    Immunity.

    (2018)
  • S.C.C. Ganal et al.

    Priming of natural killer cells by nonmucosal mononuclear phagocytes requires instructive signals from commensal microbiota

    Immunity.

    (2012)
  • J.H. Bernink et al.

    Interleukin-12 and -23 control plasticity of Cd127+ group 1 and group 3 innate lymphoid cells in the intestinal Lamina Propria

    Immunity.

    (2015)
  • N. Satoh-Takayama et al.

    Microbial flora drives interleukin 22 production in intestinal NKp46+ cells that provide innate mucosal immune defense

    Immunity.

    (2008)
  • T. Zelante et al.

    Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22

    Immunity.

    (2013)
  • J. Qiu et al.

    The aryl hydrocarbon receptor regulates gut immunity through modulation of innate lymphoid cells

    Immunity.

    (2012)
  • A. Mangalam et al.

    Human gut-derived commensal bacteria suppress CNS inflammatory and demyelinating disease

    Cell Rep.

    (2017)
  • J. Goverman et al.

    Transgenic mice that express a myelin basic protein-specific T cell receptor develop spontaneous autoimmunity

    Cell.

    (1993)
  • R.M. Ransohoff et al.

    Multiple sclerosis-a quiet revolution

    Nat. Rev. Neurol.

    (2015)
  • M. Sospedra et al.

    Immunology of multiple sclerosis

    Annu. Rev. Immunol.

    (2005)
  • A.E. Handel et al.

    Environmental factors and their timing in adult-onset multiple sclerosis

    Nat. Rev. Neurol.

    (2010)
  • International Multiple Sclerosis Genetics Consortium et al.

    Risk alleles for multiple sclerosis identified by a genomewide study

    N. Engl. J. Med.

    (2007)
  • P.L. De Jager et al.

    Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci

    Nat. Genet.

    (2009)
  • M. Bahlo et al.

    Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20

    Nat. Genet.

    (2009)
  • International Multiple Sclerosis Genetics Consortium et al.

    Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis

    Nature

    (2011)
  • K. Hirota et al.

    Fate mapping of IL-17-producing T cells in inflammatory responses

    Nat. Immunol.

    (2011)
  • L. Codarri et al.

    RORγt drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation

    Nat. Immunol.

    (2011)
  • M. El-Behi et al.

    The encephalitogenicity of TH 17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF

    Nat. Immunol.

    (2011)
  • D. Karussis

    Immunotherapy of multiple sclerosis: the state of the art

    BioDrugs.

    (2013)
  • R. Li et al.

    Reassessing B cell contributions in multiple sclerosis

    Nat. Immunol.

    (2018)
  • J.L. Croxford et al.

    Immunoregulation of multiple sclerosis by gut environmental factors

    Clin. Exp. Neuroimmunol.

    (2015)
  • R. Sender et al.

    Revised estimates for the number of human and bacteria cells in the body

    PLoS Biol.

    (2016)
  • K. Atarashi et al.

    Ectopic colonization of oral bacteria in the intestine drives TH1 cell induction and inflammation

    Science (80-.)

    (2017)
  • J.L. Round et al.

    The Toll-like receptor 2 pathway establishes colonization by a commensal of the human microbiota

    Science

    (2011)
  • J. Ochoa-Reparaz et al.

    Central nervous system demyelinating disease protection by the human commensal bacteroides fragilis depends on polysaccharide A expression

    J. Immunol.

    (2010)
  • K. Atarashi et al.

    Induction of colonic regulatory T cells by indigenous Clostridium species

    Science.

    (2011)
  • K. Atarashi et al.

    Treg induction by a rationally selected mixture of clostridia strains from the human microbiota

    Nature.

    (2013)
  • P.M. Smith et al.

    The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis

    Science.

    (2013)
  • N. Arpaia et al.

    Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation

    Nature.

    (2013)
  • Y. Furusawa et al.

    Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells

    Nature.

    (2013)
  • T. Tanoue et al.

    A defined commensal consortium elicits CD8 T cells and anti-cancer immunity

    Nature.

    (2019)
  • L.J. Carreño et al.

    Synthetic glycolipid activators of natural killer T cells as immunotherapeutic agents

    Clin. Transl. Immunol.

    (2016)
  • K. Miyamoto et al.

    A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells

    Nature.

    (2001)
  • S. Oki et al.

    The clinical implication and molecular mechanism of preferential IL-4 production by modified glycolipid-stimulated NKT cells

    J. Clin. Invest.

    (2004)
  • S. Oki et al.

    Preferential Th2 polarization by OCH is supported by incompetent NKT cell induction of CD40L and following production of inflammatory cytokines by bystander cells in vivo

    Int. Immunol.

    (2005)
  • L.C. Wieland Brown et al.

    Production of α-galactosylceramide by a prominent member of the human gut microbiota

    PLoS Biol.

    (2013)
  • Y. Kinjo et al.

    Recognition of bacterial glycosphingolipids by natural killer T cells

    Nature.

    (2005)
  • Cited by (0)

    View full text